Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion of the historical financial condition and results of operations in conjunction with our historical consolidated financial statements and accompanying notes, which are included elsewhere in this Quarterly Report on Form 10-Q. In addition, this discussion includes forward-looking statements subject to risks and uncertainties that may result in actual results differing from statements we make. See “Cautionary Note Regarding Forward-Looking Statements.” Factors that could cause actual results to differ include those risks and uncertainties discussed in “Risk Factors.”
The following discussion relates to the unaudited financial statements of Turning Point Brands, Inc., included elsewhere in this Quarterly Report on Form 10-Q. In this discussion, unless the context requires otherwise, references to “our Company” “we,” “our,” or “us” refer to Turning Point Brands, Inc., and its consolidated subsidiaries. References to “TPB” refer to Turning Point Brands, Inc., without any of its subsidiaries. We were incorporated in 2004 under the name North Atlantic Holding Company, Inc. On November 4, 2015, we changed our name to Turning Point Brands, Inc. Many of the amounts and percentages in this discussion have been rounded for convenience of presentation.
Overview
Turning Point Brands, Inc. (the “Company,” “we,” “our,” or “us”) is a leading manufacturer, marketer and distributor of branded consumer products. We sell a wide range of products to adult consumers consisting of staple products with our iconic brands Zig-Zag® and Stoker’s® to our next generation products to fulfill evolving consumer preferences. Among other markets, we compete in the alternative smoking accessories and Other Tobacco Products (“OTP”) industries. The alternative smoking accessories market is a dynamic market experiencing robust secular growth driven by cannabinoid legalization in the U.S. and Canada, and positively evolving consumer perception and acceptance in North America. The OTP industry, which consists of non-cigarette tobacco products, exhibited low double-digit consumer unit growth in 2020 as reported by Management Science Associates, Inc. (“MSAi”), a third-party analytics and information company. Our three focus segments are led by our core, proprietary brands: Zig-Zag® in the Zig-Zag Products segment; Stoker’s® along with Beech-Nut® and Trophy® in the Stoker’s Products segment; and Nu-XTM, Solace® along with our distribution platforms (Vapor Beast®, VaporFi® and Direct Vapor®) in the NewGen Products segment. Our businesses generate solid cash flow which we use to finance acquisitions, increase brand support, expand our distribution infrastructure, and strengthen our capital position. We currently ship to approximately 800 distributors with an additional 200 secondary, indirect wholesalers in the U.S. that carry and sell our products. Under the leadership of a senior management team with extensive experience in the consumer products, alternative smoking accessories and tobacco industries, we have grown and diversified our business through new product launches, category expansions, and acquisitions while concurrently improving operational efficiency.
We have identified additional growth opportunities in the emerging alternatives market. In January 2019, we established Nu-X Ventures LLC (“Nu-X”), a new wholly owned subsidiary dedicated to the development, production and sale of alternative products and acquisitions in related spaces. The creation of Nu-X allows us to leverage our expertise in traditional OTP management to alternative products. Our management team has extensive experience navigating federal, state and local regulations that are directly applicable to the growing alternatives market. In July 2019, we acquired the assets of Solace Technology (“Solace”). Solace is an innovative product development company which established one of the top e-liquid brands and has since grown into a leader in alternative products. Solace’s legacy and innovation enhanced Nu-X’s strong and nimble development engine.
We believe there are meaningful opportunities to grow through acquisitions and joint ventures across all product categories. As of December 31, 2020, our products are available in approximately 190,000 U.S. retail locations which, with the addition of retail stores in Canada, brings our total North American retail presence to an estimated 210,000 points of distribution. Our sales team targets widespread distribution to all traditional retail channels, including convenience stores, and we have a growing e-commerce business.
Products
We operate in three segments: Zig-Zag Products, Stoker’s Products and NewGen Products. In our Zig-Zag Products segment, we principally market and distribute (i) rolling papers, tubes, and related products; and (ii) finished cigars and make-your-own (“MYO”) cigar wraps. In our Stoker’s Products segment, we (i) manufacture and market moist snuff tobacco (“MST”) and (ii) contract for and market loose leaf chewing tobacco products. In our NewGen Products segment, we (i) market and distribute CBD, liquid vapor products and certain other products without tobacco and/or nicotine; (ii) distribute a wide assortment of products to non-traditional retail via VaporBeast; and (iii) market and distribute a wide assortment of products to individual consumers via the VaporFi B2C online platform.
Operations
Our core Zig-Zag Products and Stoker’s Products segments primarily generate revenues from the sale of our products to wholesale distributors who, in turn, resell the products to retail operations. In our NewGen Products segment, our acquisition of VaporBeast in 2016 expanded our revenue streams as we began selling directly to non-traditional retail outlets. Our acquisition of IVG in 2018 enhanced our B2C revenue stream with the addition of the Vapor-Fi online platform. The acquisition of Solace provided us with a line of leading liquids and a powerful new product development platform. Our net sales, which include federal excise taxes, consist of gross sales net of cash discounts, returns, and selling and marketing allowances.
We rely on long-standing relationships with high-quality, established manufacturers to provide the majority of our produced products. More than 80% of our production, as measured by net sales, is outsourced to suppliers. The remaining production consists primarily of our moist snuff tobacco operations located in Dresden, Tennessee, and Louisville, Kentucky. Our principal operating expenses include the cost of raw materials used to manufacture the limited number of our products which we produce in-house; the cost of finished products, which are generally purchased goods; federal excise taxes; legal expenses; and compensation expenses, including benefits and costs of salaried personnel. Our other principal expenses include interest expense and other expenses.
Key Factors Affecting Our Results of Operations
We consider the following to be the key factors affecting our results of operations:
| • | Our ability to further penetrate markets with our existing products; |
| • | Our ability to introduce new products and product lines that complement our core business; |
| • | Decreasing interest in some tobacco products among consumers; |
| • | Price sensitivity in our end-markets; |
| • | Marketing and promotional initiatives, which cause variability in our results; |
| • | General economic conditions, including consumer access to disposable income; |
| • | Freight and shipping costs and the availability of adequate freight for our shipments; |
| • | Cost and increasing regulation of promotional and advertising activities; |
| • | Cost of complying with regulation, including the “deeming regulations”; |
| • | Counterfeit and other illegal products in our end-markets; |
| • | Our ability to identify attractive acquisition opportunities; and |
| • | Our ability to integrate acquisitions. |
Recent Developments
Share Repurchase Authorization Increase
On October 25, 2021, the Board of Directors of Turning Point Brands increased the Company’s share repurchase authorization by $30.7 million to an aggregate amount of $50.0 million, including approximately $19.3 million available for repurchases under the Board’s previous authorization approved on February 25, 2020.
The repurchase authorization permits shares to be repurchased in open market or private transactions, through block trades, and pursuant to any trading plan or other arrangements. The timing, manner, price and amount of any repurchases will be determined by the Company’s management in its discretion and will be subject to economic and market conditions, stock price, applicable legal requirements and other factors. The repurchase authorization does not obligate the Company to purchase any specific number of shares and may be suspended or discontinued at any time.
Final Rule Related to PACT Act Published
On October 21, 2021, the United States Postal Service (“USPS”) published a Final Rule entitled “Treatment of E-Cigarettes in the Mail,” which followed its earlier publication of the Proposed Rule on February 19, 2021. This Final Rule was required as a result of the inclusion of Division FF, Title VI (Preventing Online Sales of E-Cigarettes to Children or “POSECA”) in the Further Consolidated Appropriations Act, 2021. POSECA, among other things, expanded the definition of “cigarettes” in the Jenkins Act and Prevent All Cigarette Trafficking (“PACT”) Act to expressly capture “electronic nicotine delivery systems,” i.e., ENDS. Consistent with the Proposed Rule, the Final Rule extends the existing prohibition on and exceptions to the mailing of “cigarettes” via USPS to ENDS products, other than the Consumer Testing and Public Health exceptions. Specifically, the Final Rule extends the following exceptions to the prohibition on mailing of ENDS products: the Business/Regulatory Purposes Exception, the Certain Individuals Exception, and the exception for intra-Alaska and intra-Hawaii shipments. While the Final Rule is largely in line with our expectations, we expect a transition period as we adjust our logistics.
Unitabac
On July 23, 2021, we acquired certain assets of Unitabac, a marketer of mass-market cigars, for $10.7 million in total consideration, comprised of $9.6 million in cash and $1.1 million of capitalized transaction costs. The acquisition is comprised of a robust portfolio of cigarillo products and all related intellectual property, including Cigarillo Non-Tip (NT) Homogenized Tobacco Leaf (HTL) products and Rolled Leaf and Natural Leaf Cigarillo Products.
Old Pal
On July 21, 2021, we invested $8 million in Old Pal Holding Company LLC (“Old Pal”), a leading brand in the cannabis lifestyle space. We invested in the form of a convertible note which includes additional follow-on investment rights. Old Pal is a leading brand in the cannabis space that operates a non-plant touching licensing model. Our investment will enable Old Pal to expand product offerings in existing states, which include California, Nevada, Michigan, Oklahoma, Ohio, Washington and Massachusetts, and will help create the infrastructure necessary to support continued territory and product expansion.
Direct Value Wholesale
In April 2021, ReCreation Marketing (“ReCreation”), a VIE for which we are considered the primary beneficiary, purchased 100% of the equity interest of Westhem Ventures LTD d/b/a Direct Value Wholesale (“DVW”) for $3.9 million satisfied through $3.5 million paid in cash and $0.5 million in accrued consideration to be paid during 2021. DVW is Canadian distribution entity that operates in markets not primarily served by ReCreation. The acquisition expands ReCreation’s markets in Canada.
Docklight Brands, Inc.
On April 19, 2021, we invested $8.7 million in Docklight Brands, Inc., a pioneering consumer products company with celebrated brands including Marley Natural® cannabis and Marley™ CBD. We have additional follow-on investment rights. As part of the investment, we have obtained exclusive U.S. distribution rights for Docklight’s Marley™ CBD topical products.
Senior Secured Notes and 2021 Revolving Credit Facility
On February 11, 2021, we closed a private offering (the “Offering”) of $250 million aggregate principal amount of our 5.625% senior secured notes due 2026 (the “Senior Secured Notes”). The Senior Secured Notes bear interest at a rate of 5.625% and will mature on February 15, 2026. In connection with the Offering, we also entered into a new $25 million senior secured revolving credit facility (the “2021 Revolving Credit Facility”) with the lenders party thereto (the “Lenders”) and Barclays Bank PLC, as administrative agent and collateral agent (in such capacity, the “Agent”). The 2021 Revolving Credit Facility provides for a revolving line of credit of up to $25.0 million. We used a portion of the proceeds from the issuance of the Senior Secured Notes to prepay all outstanding amounts under and terminate the 2018 First Lien Credit Facility in the first quarter of 2021 in the amount of $130.0 million, and the transaction resulted in a $5.7 million loss on extinguishment of debt. Refer to the “Long-Term Debt” section for a more complete description of our Senior Secured Notes and 2021 Revolving Credit Facility.
Premarket Tobacco Applications
We submitted Premarket Tobacco Applications (“PMTAs”) covering 250 products to the FDA prior to the September 9, 2020 filing deadline. The PMTAs cover a broad assortment of products in the vapor category including multiple proprietary e-liquid offerings in varying nicotine strengths, technologies and sizes; proprietary replacement parts and components of open system tank devices through partnerships with two leading manufacturers for exclusive distribution of products in the United States; and a closed system e-cigarette, covering $0.7 million of inventory that was quarantined as of September 30, 2021. On September 14, 2021, the FDA issued a Marketing Denial Order (“MDO”) for certain of the Company’s proprietary e-liquid products subject of these PMTAs. The Company filed a Petition for Review in the Sixth Circuit Court of Appeals on September 23, 2021, followed by an Emergency Motion for a Stay Pending Review on September 30, 2021. On October 7, 2021, we were informed that the FDA had rescinded its September 14 MDO. We therefore withdrew both the Petition and Emergency Stay on October 8, 2021. The Rescission Letter indicated that the FDA had found additional relevant information that was not adequately assessed. The Rescission Letter further clarified that the FDA presently has no intention of initiating any regulatory enforcement action against the products.
Critical Accounting Policies and Uses of Estimates
Inventories
Inventories are stated at the lower of cost or net realizable value. Effective January 1, 2021, the Company changed its method of accounting for inventory using the last-in, first-out (“LIFO”) method to the first-in, first-out (“FIFO”) method. The Company applied this change retrospectively to all prior periods presented, which is discussed further in Note 6, “Inventories” in the Notes to the Consolidated Financial Statements included in this Quarterly Report. Leaf tobacco is presented in current assets in accordance with standard industry practice, notwithstanding the fact that such tobaccos are carried longer than one year for the purpose of curing.
There have been no other material changes to our critical accounting policies and estimates from the information provided in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2020 Annual Report on Form 10-K.
Recent Accounting Pronouncements
Refer to Note 2, “Summary of Significant Accounting Policies,” of Notes to Consolidated Financial Statements included in this Quarterly Report for a description of recently issued accounting pronouncements, including those recently adopted.
Results of Operations
Comparison of the Three Months Ended September 30, 2021, to the Three Months Ended September 30, 2020
The table and discussion set forth below displays our consolidated results of operations (in thousands):
| | Three Months Ended September 30, | |
| | 2021 | | | 2020 | | | % Change | |
Consolidated Results of Operations Data: | | | | | | | | | |
Net sales | | | | | | | | | |
Zig-Zag products | | $ | 42,234 | | | $ | 35,973 | | | | 17.4 | % |
Stoker’s products | | | 30,472 | | | | 29,764 | | | | 2.4 | % |
NewGen products | | | 37,198 | | | | 38,437 | | | | -3.2 | % |
Total net sales | | | 109,904 | | | | 104,174 | | | | 5.5 | % |
Cost of sales | | | 55,635 | | | | 55,867 | | | | -0.4 | % |
Gross profit | | | | | | | | | | | | |
Zig-Zag products | | | 23,703 | | | | 21,263 | | | | 11.5 | % |
Stoker’s products | | | 17,104 | | | | 16,042 | | | | 6.6 | % |
NewGen products | | | 13,462 | | | | 11,002 | | | | 22.4 | % |
Total gross profit | | | 54,269 | | | | 48,307 | | | | 12.3 | % |
| | | | | | | | | | | | |
Selling, general, and administrative expenses | | | 31,894 | | | | 32,286 | | | | -1.2 | % |
Operating income | | | 22,375 | | | | 16,021 | | | | 39.7 | % |
Interest expense, net | | | 5,397 | | | | 3,539 | | | | 52.5 | % |
Investment income | | | (157 | ) | | | (3 | ) | | | 5133.3 | % |
Gain on extinguishment of debt | | | (375 | ) | | | - | | | NM | |
Net periodic income, excluding service cost | | | - | | | | 1,188 | | | | -100.0 | % |
Income before income taxes | | | 17,510 | | | | 11,297 | | | | 55.0 | % |
Income tax expense | | | 4,073 | | | | 2,277 | | | | 78.9 | % |
Consolidated net income | | | 13,437 | | | | 9,020 | | | | 49.0 | % |
Net loss attributable to non-controlling interest | | | (31 | ) | | | - | | | NM | |
Net income attributable to Turning Point Brands, Inc. | | $ | 13,468 | | | $ | 9,020 | | | | 49.3 | % |
Net Sales: For the three months ended September 30, 2021, consolidated net sales increased to $109.9 million from $104.2 million for the three months ended September 30, 2020, an increase of $5.7 million or 5.5%. The increase in net sales was primarily driven by increased sales volume in the Zig-Zag Products segment.
For the three months ended September 30, 2021, net sales in the Zig-Zag Products segment increased to $42.2 million from $36.0 million for the three months ended September 30, 2020, an increase of $6.3 million or 17.4%. For the three months ended September 30, 2021, volume increased 17.0% and price/mix increased 0.4%. The increase in net sales was led by our Canadian business which benefited from the consolidation of ReCreation in the current year period. This growth was complemented by double-digit growth in U.S. rolling papers and our E-Commerce business.
For the three months ended September 30, 2021, net sales in the Stoker’s Products segment increased to $30.5 million from $29.8 million for the three months ended September 30, 2020, an increase of $0.7 million or 2.4%. For the three months ended September 30, 2021, volume decreased 4.1% and price/mix increased 6.5%. The increase in net sales was driven by the continuing double-digit growth of Stoker’s® MST offset by single-digit decline in loose-leaf chewing tobacco.
For the three months ended September 30, 2021, net sales in the NewGen products segment decreased to $37.2 million from $38.4 million for the three months ended September 30, 2020, a decrease of $1.2 million or 3.2%. The decrease in net sales was primarily the result of declines in the vape distribution businesses as a result of strong B2C orders during stay-at-home provisions in the prior year.
Gross Profit: For the three months ended September 30, 2021, consolidated gross profit increased to $54.3 million from $48.3 million for the three months ended September 30, 2020, an increase of $6.0 million or 12.3%. Gross profit as a percentage of revenue increased to 49.4% for the three months ended September 30, 2021, compared to 46.4% for the three months ended September 30, 2020 driven by increased margin in the NewGen Products and Stoker’s Products segments.
For the three months ended September 30, 2021, gross profit in the Zig-Zag Products segment increased to $23.7 million from $21.3 million for the three months ended September 30, 2020, an increase of $2.4 million or 11.5%. Gross profit as a percentage of net sales decreased to 56.1% of net sales for the three months ended September 30, 2021, from 59.1% of net sales for the three months ended September 30, 2020, as a result of the consolidation of ReCreation in the current year period which operates at lower margins than our traditional business.
For the three months ended September 30, 2021, gross profit in the Stoker’s Products segment increased to $17.1 million from $16.0 million for the three months ended September 30, 2020, an increase of $1.1 million or 6.6%. Gross profit as a percentage of net sales increased to 56.1% of net sales for the three months ended September 30, 2021, from 53.9% of net sales for the three months ended September 30, 2020, primarily as a result of strong incremental margin contribution of MST.
For the three months ended September 30, 2021, gross profit in the NewGen products segment increased to $13.5 million from $11.0 million for the three months ended September 30, 2020, an increase of $2.5 million or 22.4%. Gross profit as a percentage of net sales increased to 36.2% of net sales for the three months ended September 30, 2021, from 28.6% of net sales for the three months ended September 30, 2020, primarily as a result of increased margins in the vape distribution businesses.
Selling, General, and Administrative Expenses: For the three months ended September 30, 2021, selling, general, and administrative expenses decreased to $31.9 million from $32.3 million for the three months ended September 30, 2020, a decrease of $0.4 million or 1.2%. Selling, general and administrative expenses in the three months ended September 30, 2021 included $1.8 million of stock options, restricted stock and incentives expense, $0.2 million of transaction income and $1.0 million of expense related to PMTA. Selling, general and administrative expenses in the three months ended September 30, 2020 included $0.8 million of stock option, restricted stock and incentives expense, $0.6 million of transaction costs and $5.3 million of expense related to PMTA. The increase in selling, general, and administrative expenses is the result of variable costs in our online businesses as well as increased shipping costs from PACT Act implementation for vape products and higher freight rates across all segments combined with the impact of the consolidation of ReCreation in the current year period.
Interest Expense, net: For the three months ended September 30, 2021, interest expense, net increased to $5.4 million, from $3.5 million for the three months ended September 30, 2020 as a result of the completion of the offering of the Senior Secured Notes and related refinancing of the 2018 First Lien Credit Facility which increased the Company’s outstanding debt.
Investment Income: For the three months ended September 30, 2021, investment income increased to $0.2 million, from $0.0 million for the three months ended September 30, 2020.
Gain on Extinguishment of Debt: Gain on extinguishment of debt was $0.4 million for the three months ended September 30, 2021 related to the entire repayment of the $10 million Promissory Note from the acquisition of certain Durfort assets for a total payment of $9.6 million, compared to $0.0 million for the three months ended September 30, 2020.
Net Periodic Income: Net periodic income was $0.0 million for the three months ended September 30, 2021 compared to $1.2 million for the three months ended September 30, 2020.
Income Tax Expense: Our income tax expense of $4.1 million was 23.3% of income before income taxes for the three months ended September 30, 2021 and included a discrete tax benefit of $1.0 million relating to stock option exercises. Our effective income tax rate was 20.2% for the three months ended September 30, 2020 and included a discrete tax benefit $0.6 million from the shutdown of the pension plan.
Net Loss Attributable to Non-Controlling Interest: Net loss attributable to non-controlling interest was $0.0 million for the three months ended September 30, 2021 compared to $0.0 million for the three months ended September 30, 2020.
Net Income Attributable to Turning Point Brands, Inc.: Due to the factors described above, net income attributable to Turning Point Brands, Inc. for the three months ended September 30, 2021 and 2020, was $13.5 million and $9.0 million, respectively.
Comparison of the Nine Months Ended September 30, 2021, to the Nine Months Ended September 30, 2020
The table and discussion set forth below displays our consolidated results of operations (in thousands):
| | Nine Months Ended September 30, | |
| | 2021 | | | 2020 | | | % Change | |
Consolidated Results of Operations Data: | | | | | | | | | |
Net sales | | | | | | | | | |
Zig-Zag products | | $ | 130,440 | | | $ | 92,290 | | | | 41.3 | % |
Stoker’s products | | | 93,096 | | | | 87,081 | | | | 6.9 | % |
NewGen products | | | 116,652 | | | | 120,455 | | | | -3.2 | % |
Total net sales | | | 340,188 | | | | 299,826 | | | | 13.5 | % |
Cost of sales | | | 172,685 | | | | 162,152 | | | | 6.5 | % |
Gross profit | | | | | | | | | | | | |
Zig-Zag products | | | 76,342 | | | | 53,066 | | | | 43.9 | % |
Stoker’s products | | | 51,142 | | | | 46,424 | | | | 10.2 | % |
NewGen products | | | 40,019 | | | | 38,184 | | | | 4.8 | % |
Total gross profit | | | 167,503 | | | | 137,674 | | | | 21.7 | % |
| | | | | | | | | | | | |
Selling, general, and administrative expenses | | | 95,900 | | | | 95,436 | | | | 0.5 | % |
Operating income | | | 71,603 | | | | 42,238 | | | | 69.5 | % |
Interest expense, net | | | 15,406 | | | | 10,143 | | | | 51.9 | % |
Investment income | | | (292 | ) | | | (128 | ) | | | 128.1 | % |
Loss on extinguishment of debt | | | 5,331 | | | | - | | | NM | |
Net periodic income, excluding service cost | | | - | | | | 997 | | | | -100.0 | % |
Income before income taxes | | | 51,158 | | | | 31,226 | | | | 63.8 | % |
Income tax expense | | | 11,151 | | | | 7,412 | | | | 50.4 | % |
Consolidated net income | | | 40,007 | | | | 23,814 | | | | 68.0 | % |
Net loss attributable to non-controlling interest | | | (598 | ) | | | - | | | NM | |
Net income attributable to Turning Point Brands, Inc. | | $ | 40,605 | | | $ | 23,814 | | | | 70.5 | % |
Net Sales: For the nine months ended September 30, 2021, consolidated net sales increased to $340.2 million from $299.8 million for the nine months ended September 30, 2020, an increase of $40.4 million or 13.5%. The increase in net sales was primarily driven by increased sales volume in the Zig-Zag Products segment.
For the nine months ended September 30, 2021, net sales in the Zig-Zag Products segment increased to $130.4 million from $92.3 million for the nine months ended September 30, 2020, an increase of $38.2 million or 41.3%. For the nine months ended September 30, 2021, volume increased 37.3% and price/mix increased 4.0%. The increase in net sales was led by double-digit growth in sales of our MYO cigar wraps business, which experienced COVID-related manufacturing disruption in the prior year period. This growth was complemented by our Canadian business which benefited from the consolidation of ReCreation in the current year period and double-digit growth in U.S. rolling papers.
For the nine months ended September 30, 2021, net sales in the Stoker’s Products segment increased to $93.1 million from $87.1 million for the nine months ended September 30, 2020, an increase of $6.0 million or 6.9%. For the nine months ended September 30, 2021, volume increased 1.0% and price/mix increased 5.9%. The increase in net sales was driven by the continuing double-digit growth of Stoker’s® MST offset by low single-digit decline in loose-leaf chewing tobacco.
For the nine months ended September 30, 2021, net sales in the NewGen products segment decreased to $116.7 million from $120.5 million for the nine months ended September 30, 2020, a decrease of $3.8 million or 3.2%. The decrease in net sales was primarily the result of declines in the vape distribution businesses as a result of strong B2C orders during stay-at-home provisions in the prior year.
Gross Profit: For the nine months ended September 30, 2021, consolidated gross profit increased to $167.5 million from $137.7 million for the nine months ended September 30, 2020, an increase of $29.8 million or 21.7%. Gross profit as a percentage of revenue increased to 49.2% for the nine months ended September 30, 2021, compared to 45.9% for the nine months ended September 30, 2020 driven by increased margin in the Zig-Zag Products segment as a result of the Durfort transaction in June 2020.
For the nine months ended September 30, 2021, gross profit in the Zig-Zag Products segment increased to $76.3 million from $53.1 million for the nine months ended September 30, 2020, an increase of $23.3 million or 43.9%. Gross profit as a percentage of net sales increased to 58.5% of net sales for the nine months ended September 30, 2021, from 57.5% of net sales for the nine months ended September 30, 2020, as a result of increased MYO cigar wraps sales combined with margin increases as a result of the Durfort transaction in September 2020.
For the nine months ended September 30, 2021, gross profit in the Stoker’s Products segment increased to $51.1 million from $46.4 million for the nine months ended September 30, 2020, an increase of $4.7 million or 10.2%. Gross profit as a percentage of net sales increased to 54.9% of net sales for the nine months ended September 30, 2021, from 53.3% of net sales for the nine months ended September 30, 2020, primarily as a result of strong incremental margin contribution of MST.
For the nine months ended September 30, 2021, gross profit in the NewGen products segment increased to $40.0 million from $38.2 million for the nine months ended September 30, 2020, an increase of $1.8 million or 4.8%. Gross profit as a percentage of net sales increased to 34.3% of net sales for the nine months ended September 30, 2021, from 31.7% of net sales for the nine months ended September 30, 2020, primarily as a result of increased margins in the vape distribution businesses.
Selling, General, and Administrative Expenses: For the nine months ended September 30, 2021, selling, general, and administrative expenses increased to $95.9 million from $95.4 million for the nine months ended September 30, 2020, an increase of $0.5 million or 0.5%. Selling, general and administrative expenses in the nine months ended September 30, 2021 included $6.0 million of stock options, restricted stock and incentives expense (including $1.1 million for accelerated vesting of options for a departing executive), $1.1 million of transaction expenses and $1.9 million of expenses related to PMTA. Selling, general and administrative expenses in the nine months ended September 30, 2020 included $2.0 million of stock option, restricted stock and incentives expense, $1.9 million of transaction costs and $14.4 million of expense related to PMTA. The increase in selling, general, and administrative expenses is the result of variable costs in our online businesses as well as increased shipping costs from PACT Act implementation for vape products and higher freight rates across all segments combined with the impact of the consolidation of ReCreation in the current year period.
Interest Expense, net: For the nine months ended September 30, 2021, interest expense, net increased to $15.4 million, from $10.1 million for the nine months ended September 30, 2020 as a result of the completion of the offering of the Senior Secured Notes and related refinancing of the 2018 First Lien Credit Facility which increased the Company’s outstanding debt.
Investment Income: For the nine months ended September 30, 2021, investment income increased to $0.3 million, from $0.1 million for the nine months ended September 30, 2020.
Loss on Extinguishment of Debt: Loss on extinguishment of debt was $5.3 million for the nine months ended September 30, 2021 related primarily to the repayment of the 2018 First Lien Credit Facility, compared to $0.0 million for the nine months ended September 30, 2020.
Net Periodic Income: Net periodic income was $0.0 million for the nine months ended September 30, 2021 compared to $1.0 million for the nine months ended September 30, 2020.
Income Tax Expense: Our income tax expense of $11.2 million was 21.8% of income before income taxes for the nine months ended September 30, 2021 and included a discrete tax benefit of $6.2 million relating to stock option exercises. Our effective income tax rate was 23.7% for the nine months ended September 30, 2020 and included a discrete tax deduction $0.9 million relating to stock option exercises and a discrete tax benefit of $0.6 million from the shutdown of the pension plan.
Net Loss Attributable to Non-Controlling Interest: Net loss attributable to non-controlling interest was $0.6 million for the nine months ended September 30, 2021 compared to $0.0 million for the nine months ended September 30, 2020.
Net Income Attributable to Turning Point Brands, Inc.: Due to the factors described above, net income attributable to Turning Point Brands, Inc. for the nine months ended September 30, 2021 and 2020, was $40.6 million and $23.8 million, respectively.
EBITDA and Adjusted EBITDA
To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we use non-U.S. GAAP financial measures including EBITDA and Adjusted EBITDA. We believe Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to our financial condition and results of operations. Adjusted EBITDA is used by management to compare our performance to that of prior periods for trend analyses and planning purposes and is presented to our Board of Directors. We believe that EBITDA and Adjusted EBITDA are appropriate measures of operating performance because they eliminate the impact of expenses that do not relate to operating performance. In addition, our Revolving Credit Agreement contains financial covenants which use Adjusted EBITDA calculations, and many of the carve-outs from the negative covenants in the Senior Secured Notes Indenture and Revolving Credit Facility are based off of EBITDA, Adjusted EBITDA and related metrics.
We define “EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation, and amortization. We define “Adjusted EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation, amortization, other non-cash items, and other items we do not consider ordinary course in our evaluation of ongoing operating performance noted in the reconciliation below.
Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. Adjusted EBITDA excludes significant expenses required to be recorded in our financial statements by U.S. GAAP and is subject to inherent limitations. Other companies in our industry may calculate this non-U.S. GAAP measure differently than we do or may not calculate it at all, limiting its usefulness as a comparative measure. The tables below provide reconciliations between net income and Adjusted EBITDA.
(in thousands) | | Three Months Ended September 30, | |
| | 2021 | | | 2020 | |
Net income attributable to Turning Point Brands, Inc. | | $ | 13,468 | | | $ | 9,020 | |
Add: | | | | | | | | |
Interest expense, net | | | 5,397 | | | | 3,539 | |
Gain on extinguishment of debt | | | (375 | ) | | | - | |
Income tax expense | | | 4,073 | | | | 2,277 | |
Depreciation expense | | | 767 | | | | 809 | |
Amortization expense | | | 477 | | | | 477 | |
EBITDA | | $ | 23,807 | | | $ | 16,122 | |
Components of Adjusted EBITDA | | | | | | | | |
Other (a) | | | - | | | | 1,188 | |
Stock options, restricted stock, and incentives expense (b) | | | 1,752 | | | | 772 | |
Transactional expenses (c) | | | (232 | ) | | | 570 | |
FDA PMTA (d) | | | 960 | | | | 5,271 | |
Adjusted EBITDA | | $ | 26,287 | | | $ | 23,923 | |
(a) | Represents non-cash pension expense (income) and foreign exchange hedging. |
(b) | Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units. |
(c) | Represents the fees incurred for transaction expenses. |
(d) | Represents costs associated with applications related to FDA premarket tobacco product application (“PMTA”). |
(in thousands) | | Nine Months Ended September 30, | |
| | 2021 | | | 2020 | |
Net income attributable to Turning Point Brands, Inc. | | $ | 40,605 | | | $ | 23,814 | |
Add: | | | | | | | | |
Interest expense, net | | | 15,406 | | | | 10,143 | |
Loss on extinguishment of debt | | | 5,331 | | | | - | |
Income tax expense | | | 11,151 | | | | 7,412 | |
Depreciation expense | | | 2,313 | | | | 2,482 | |
Amortization expense | | | 1,431 | | | | 1,304 | |
EBITDA | | $ | 76,237 | | | $ | 45,155 | |
Components of Adjusted EBITDA | | | | | | | | |
Other (a) | | | - | | | | 841 | |
Stock options, restricted stock, and incentives expense (b) | | | 6,015 | | | | 1,987 | |
Transactional expenses (c) | | | 1,077 | | | | 1,909 | |
FDA PMTA (d) | | | 960 | | | | 14,435 | |
Adjusted EBITDA | | $ | 84,289 | | | $ | 64,327 | |
(a) | Represents non-cash pension expense (income) and foreign exchange hedging. |
(b) | Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units. |
(c) | Represents the fees incurred for transaction expenses. |
(d) | Represents costs associated with applications related to FDA premarket tobacco product application (“PMTA”). |
Liquidity and Capital Reserves
Our principal uses for cash are working capital, debt service, and capital expenditures. We believe our cash on hand, cash flows from operations and borrowing availability under our 2021 Revolving Credit Facility are adequate to satisfy our operating cash requirements for the foreseeable future. As of September 30, 2021, we had $130.6 million of cash on hand and have $21.4 million of availability under the 2021 Revolving Credit Facility.
Our working capital, which we define as current assets less cash and current liabilities, increased $15.2 million to $80.2 million at September 30, 2021, compared with $65.0 million at December 31, 2020. The increase was primarily due to the increase in inventories as a result of increased sales.
| | As of | |
(in thousands) | | September 30, 2021 | | | December 31, 2020 | |
| | | | | | |
Current assets | | $ | 134,225 | | | $ | 121,638 | |
Current liabilities | | | 54,056 | | | | 56,629 | |
Working capital | | $ | 80,169 | | | $ | 65,009 | |
Cash Flows from Operating Activities
For the nine months ended September 30, 2021, net cash provided by operating activities was $49.6 million compared to net cash provided by operating activities of $33.2 million for the nine months ended September 30, 2020, an increase of $16.4 million, primarily due to higher net income resulting from increased sales.
Cash Flows from Investing Activities
For the nine months ended September 30, 2021, net cash used in investing activities was $52.2 million compared to net cash used in investing activities of $41.2 million for the nine months ended September 30, 2020, an increase of $11.1 million, primarily due to the purchase of investments in our MSA escrow account which reflects the change in restricted cash.
Cash Flows from Financing Activities
For the nine months ended September 30, 2021, net cash provided by financing activities was $76.3 million compared to net cash used in financing activities of $16.9 million for the nine months ended September 30, 2020, an increase in cash flow of $93.2 million, primarily due to the net proceeds from the Senior Secured Notes partially offset by the repayment in full of the 2018 First Lien Term Loan in the first quarter of 2021 and the repurchase of common stock during 2021.
Dividends and Share Repurchase
The most recent dividend of $0.055 per common share was paid on October 8, 2021, to shareholders of record at the close of business on September 17, 2021.
On February 25, 2020, our Board of Directors approved a $50.0 million share repurchase program, which is intended for opportunistic execution based upon a variety of factors including market dynamics. The program is subject to the ongoing discretion of the Board. The total number of shares repurchased for the three months ended September 30, 2021, was 125,000 shares for a total cost of $6.4 million and an average price per share of $51.16. $19.3 million remains available for share repurchases under the program at September 30, 2021.
Long-Term Debt
As of September 30, 2021, we were in compliance with the financial and restrictive covenants of the Senior Secured Notes and 2021 Revolving Credit Facility. The following table provides outstanding balances of our debt instruments.
| | September 30, 2021 | | | December 31, 2020 | |
Senior Secured Notes | | $ | 250,000 | | | $ | - | |
2018 First Lien Term Loan | | | - | | | | 130,000 | |
Convertible Senior Notes | | | 172,500 | | | | 172,500 | |
Note payable - Promissory Note | | | - | | | | 10,000 | |
Note payable - Unsecured Loan | | | 7,485 | | | | 7,485 | |
Gross notes payable and long-term debt | | | 429,985 | | | | 319,985 | |
Less deferred finance charges | | | (8,947 | ) | | | (5,873 | ) |
Less current maturities | | | (7,485 | ) | | | (12,000 | ) |
Notes payable and long-term debt | | $ | 413,553 | | | $ | 302,112 | |
Senior Secured Notes
On February 11, 2021, we closed a private offering (the “Offering”) of $250 million aggregate principal amount of our 5.625% senior secured notes due 2026 (the “Senior Secured Notes”). The Senior Secured Notes bear interest at a rate of 5.625% and will mature on February 15, 2026. Interest on the Senior Secured Notes is payable semi-annually in arrears on February 15 and August 15 of each year, commencing on August 15, 2021.We used the proceeds from the Offering (i) to repay all obligations under and terminate the 2018 First Lien Credit Facility, (ii) to pay related fees, costs, and expenses and (iii) for general corporate purposes.
Obligations under the Senior Secured Notes are guaranteed by the Company’s existing and future wholly-owned domestic subsidiaries (the “Guarantors”) that guarantee any Credit Facility (as defined in the Indenture governing the Senior Secured Notes or the “Senior Secured Notes Indenture”) or capital markets debt securities of the Company or Guarantors in excess of $15.0 million. The Senior Secured Notes and the related guarantees are secured by first-priority liens on substantially all of the assets of the Company and the Guarantors, subject to certain exceptions.
We may redeem the Senior Secured Notes, in whole or in part, at any time prior to February 15, 2023, at a price equal to 100% of the principal amount of the Notes redeemed plus accrued and unpaid interest, if any, to, but excluding the applicable redemption date, plus a “make-whole” premium. Thereafter, we may redeem the Senior Secured Notes, in whole or in part, at established redemption prices set forth in the Senior Secured Notes Indenture, plus accrued and unpaid interest, if any. In addition, on or prior to February 15, 2023, we may redeem up to 40% of the aggregate principal amount of the Senior Secured Notes with the net cash proceeds from certain equity offerings at a redemption price equal to 105.625%, plus accrued and unpaid interest, if any to the redemption date; provided, however, that at least 50% of the original aggregate principal amount of the Senior Secured Notes (calculated after giving effect to the issuance of any additional notes) remains outstanding. In addition, at any time and from time to time prior to February 15, 2023, but not more than once in any twelve-month period, we may redeem up to 10% of the aggregate principal amount of the Senior Secured Notes at a redemption price of 103% of the aggregate principal amount of Senior Secured Notes redeemed plus accrued and unpaid interest, if any to but not including the redemption date, on the Senior Secured Notes to be redeemed.
If we experience a change of control (as defined in the Senior Secured Notes Indenture), we must offer to repurchase the Senior Secured Notes at a repurchase price equal to 101% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest.
The Indenture contains covenants that, among other things, restrict the ability of the Company and its restricted subsidiaries to: (i) grant or incur liens; (ii) incur, assume or guarantee additional indebtedness; (iii) sell or otherwise dispose of assets, including capital stock of subsidiaries; (iv) make certain investments; (v) pay dividends, make distributions or redeem or repurchase capital stock; (vi) engage in certain transactions with affiliates; and (vii) consolidate or merge with or into, or sell substantially all of our assets to another entity. These covenants are subject to a number of limitations and exceptions set forth in the Indenture.
We incurred debt issuance costs attributable to the issuance of the Senior Secured Notes of $6.4 million which are amortized to interest expense using the effective interest method over the expected life of the Senior Secured Notes.
The Indenture provides for customary events of default.
2021 Revolving Credit Facility
In connection with the Offering, we also entered into a new $25 million senior secured revolving credit facility (the “2021 Revolving Credit Facility”) with the lenders party thereto (the “Lenders”) and Barclays Bank PLC, as administrative agent and collateral agent (in such capacity, the “Agent”). The 2021 Revolving Credit Facility provides for a revolving line of credit of up to $25.0 million. Letters of credit are limited to $10 million (and are a part of, and not in addition to, the revolving line of credit). We have not drawn any borrowings under the 2021 Revolving Credit Facility but do have letters of credit of approximately $3.6 million outstanding under the facility. The 2021 Revolving Credit Facility will mature on August 11, 2025 if none of our Convertible Senior Notes are outstanding, and if any Convertible Senior Notes are outstanding, the date which is 91 days prior to the maturity date of July 15, 2024 for such Convertible Senior Notes.
Interest is payable on the 2021 Revolving Credit Facility at a fluctuating rate of interest determined by reference to the Eurodollar rate plus an applicable margin of 3.50% (with step-downs upon de-leveraging). We also have the option to borrow at a rate determined by reference to the base rate.
The obligations under the 2021 Revolving Credit Agreement are guaranteed on a joint and several basis by the Guarantors. The Company’s and Guarantors’ obligations under the 2021 Revolving Credit Facility are secured on a pari passu basis with the Senior Secured Notes.
The 2021 Revolving Credit Agreement contains covenants that are substantially the same as the covenants in the Senior Secured Notes Indenture. The 2021 Revolving Credit Facility also requires the maintenance of a Consolidated Leverage Ratio (as defined in the 2021 Revolving Credit Agreement) of 5.50 to 1.00 (with a step down to 5.25 to 1.00 beginning with the fiscal quarter ending March 31, 2023) at the end of each fiscal quarter when extensions of credit under the 2021 Revolving Credit Facility and certain drawn and undrawn letters of credit (excluding (a) letters of credit that have been cash collateralized and (b) letters of credit having an aggregate face amount less than $5,000,000) in the aggregate outstanding exceeds 35% of the total commitments under the 2021 Revolving Credit Facility.
We incurred debt issuance costs attributable to the issuance of the 2021 Revolving Credit Facility of $0.5 million which are amortized to interest expense using the effective interest method over the expected life of the 2021 Revolving Credit Facility.
The 2021 Revolving Credit Agreement provides for customary events of default.
2018 Credit Facility
In the first quarter of 2021, we used a portion of the proceeds from the issuance of the Senior Secured Notes to prepay all outstanding amounts under and terminate the 2018 First Lien Credit Facility in the amount of $130.0 million, and the transaction resulted in a $5.7 million loss on extinguishment of debt. See Note 11, “Notes Payable and Long-Term Debt,” in the Notes to Consolidated Financial Statements included in this Quarterly Report for further discussion.
Convertible Senior Notes
In July 2019 we closed an offering of $172.5 million in aggregate principal amount of our 2.50% Convertible Senior Notes due July 15, 2024 (the “Convertible Senior Notes”). The Convertible Senior Notes bear interest at a rate of 2.50% per year, payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The Convertible Senior Notes will mature on July 15, 2024, unless earlier repurchased, redeemed or converted. The Convertible Senior Notes are senior unsecured obligations.
The Convertible Senior Notes are convertible into approximately 3,207,293 shares of our voting common stock under certain circumstances prior to maturity at a conversion rate of 18.593 shares per $1,000 principal amount of the Convertible Senior Notes, which represents a conversion price of approximately $53.78 per share, subject to adjustment under certain conditions, but will not be adjusted for any accrued and unpaid interest. The conversion price is adjusted periodically as a result of dividends paid by the us in excess of pre-determined thresholds of $0.04 per share. Upon conversion, we may pay cash, shares of our common stock or a combination of cash and stock, as determined by us at our discretion. The conditions required to allow the holders to convert their Convertible Senior Notes were not met as of September 30, 2021.
We early adopted ASU 2020-06 effective January 1, 2021 on a retrospective basis to all periods presented. Under ASU 2020-06, the Company will account for the Convertible Senior Notes entirely as a liability and will no longer separately account for the Convertible Senior Notes with liability and equity components. See Note 2, “Summary of Significant Accounting Policies,” in the Notes to Consolidated Financial Statements included in this Quarterly Report for further discussion of the impact of the adoption of ASU 2020-06.
We incurred debt issuance costs attributable to the Convertible Senior Notes of $5.9 million which are amortized to the interest expense using the effective interest method over the expected life of the Convertible Senior Notes.
In connection with the Convertible Senior Notes offering, we entered into privately negotiated capped call transactions with certain financial institutions. The capped call transactions have a strike price of $53.78 per and a cap price of $82.86 per share, and are exercisable when, and if, the Convertible Senior Notes are converted. We paid $20.53 million for these capped calls at the time they were entered into and charged that amount to additional paid-in capital.
The indenture covering the Convertible Senior Notes contains customary events of default.
Promissory Note
On June 10, 2020, in connection with the acquisition of certain Durfort assets, we issued an unsecured subordinated promissory note (“Promissory Note”) in the principal amount of $10.0 million (the “Principal Amount”), with an annual interest rate of 7.5%, payable quarterly, with the first interest payment due September 10, 2020. The Principal Amount was payable in two $5.0 million installments, with the first installment due 18 months after the closing date of the acquisition (June 10, 2020), and the second installment due 36 months after the closing date of the acquisition. The second installment was subject to reduction for certain amounts payable to us as a holdback. We prepaid all outstanding amounts under and terminated the Promissory Note in the third quarter of 2021 in the amount of $9.6 million. The transaction resulted in a $0.4 million gain on extinguishment of debt.
Unsecured Loan
On April 6, 2020, the 2018 First Lien Credit Facility was amended to allow for an unsecured loan under the Coronavirus Aid, Relief, and Economic Security Act of 2020 (“CARES”). On April 17, 2020, National Tobacco Company, L.P., a wholly-owned subsidiary of the Company, entered into a loan agreement with Regions Bank guaranteed by the Small Business Administration for a $7.5 million unsecured loan. The proceeds of the loan were received on April 27, 2020. The loan is scheduled to mature on April 17, 2022 and has a 1.00% interest rate. During 2021, we applied for forgiveness for the loan. On October 15, 2021, we received notice that our application for forgiveness was fully approved. We anticipate that the extinguishment of the unsecured loan will occur in the fourth quarter of 2021.
Off-balance Sheet Arrangements
During the nine months ended September 30, 2021, the Company did not execute any forward contracts. At September 30, 2021, the Company had forward contracts for the purchase of €3.3 million and sale of €3.6 million outstanding. The fair value of the foreign currency contracts was based on quoted market prices and resulted in an asset of $0.0 million included in Other current assets and liability of $0.0 million included in Accrued liabilities at September 30, 2021. During 2020, the Company executed various forward contracts for the purchase of €19.7 million and sale of €21.4 million with maturity dates ranging from December 2020 to November 2021. At December 31, 2020, the Company had forward contracts for the purchase of €18.0 million and sale of €19.6 million outstanding. The fair value of the foreign currency contracts is based on quoted market prices and resulted in an asset of $0.4 million included in Other current assets and liability of $0.0 million included in Accrued liabilities at December 31, 2020. The Company had interest rate swap contracts for a notional amount of $70 million at December 31, 2020. The fair values of the interest rate swap contracts are based upon quoted market prices and resulted in a liability of $3.7 million as of December 31, 2020, included in other long-term liabilities. The Company terminated the interest rate swap agreement in conjunction with the prepayment of all outstanding amounts under to the 2018 First Lien Credit Facility in the first quarter of 2021 in the amount of $3.6 million, and the transaction resulted in a $5.7 million loss recorded in the loss on extinguishment of debt. See Note 11, “Notes Payable and Long-Term Debt,” in the Notes to Consolidated Financial Statements included in this Quarterly Report for further discussion.
Inflation
While the rate of inflation has increased recently, we believe that any effect of inflation at current levels will be minimal. Historically, we have been able to increase prices at a rate equal to or greater than that of inflation and believe that we will continue to be able to do so for the foreseeable future. In addition, we have been able to maintain a relatively stable variable cost structure for our products due, in part, to our successful procurement with regard to our tobacco products and, in part, to our existing contractual agreement for the purchase of our premium cigarette papers. However, if the rate of inflation were to increase materially, it could have an adverse effect on our results of operations.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Foreign Currency Sensitivity
There have been no material changes in our exposure to exchange rate fluctuation risk, as reported within our 2020 Annual Report on Form 10-K, during the period. Please refer to our ‘Quantitative and Qualitative Disclosures about Market Risk’ included in our 2020 Annual Report on Form 10-K filed with the SEC.
Credit Risk
There have been no material changes in our exposure to credit risk, as reported within our 2020 Annual Report on Form 10-K, during the nine months ended September 30, 2021. Please refer to our ‘Quantitative and Qualitative Disclosures about Market Risk’ included in our 2020 Annual Report on Form 10-K filed with the SEC.
Interest Rate Sensitivity
In February 2021, we issued the Senior Secured Notes in an aggregate principal amount of $250 million. In July 2019, we issued Convertible Senior Notes in an aggregate principal amount of $172.5 million. We carry the Senior Secured Notes and Convertible Senior Notes at face value. Since the Senior Secured Notes and Convertible Senior Notes bear interest at a fixed rate, we have no financial statement risk associated with changes in interest rates. However, the fair value of the Convertible Senior Notes changes when the market price of our stock fluctuates, or interest rates change. Our remaining debt instruments bear interest at fixed rates and are not subject to interest rate volatility.
Item 4. Controls and Procedures
We have carried out an evaluation under the supervision, and with the participation of, our management including our Chief Executive Officer (“CEO”), Chief Financial Officer (“CFO”), and Chief Accounting Officer (“CAO”), of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended (the “Act”)) as of September 30, 2021. Based upon the evaluation, our CEO, CFO, and CAO concluded our disclosure controls and procedures are effective to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Act is: (i) recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosures.
There have been no changes in the Company’s internal control over financial reporting during the fiscal quarter ended September 30, 2021 which have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II—OTHER INFORMATION
Item 1. Legal Proceedings For a description of our material pending legal proceedings, please see Contingencies in Note 16 to the Notes to the Consolidated Financial Statements in Part I, Item 1 of this Quarterly Report.
See ‘Risk Factors—We may become subject to significant product liability litigation’ within our 2020 Annual Report on Form 10-K for additional details.
In addition to the other information set forth in this report, carefully consider the factors discussed in the ‘Risk Factors’ section contained in our 2020 Annual Report on Form 10-K. There have been no material changes to the Risk Factors set forth in the 2020 Annual Report on Form 10-K with the exception of the below.
Many of our NewGen and cigar products have not obtained premarket authorization from the FDA and are currently marketed pursuant to a policy of FDA enforcement discretion, which could change. There could be a material adverse impact on our NewGen business development efforts if the FDA determines that our products are not subject to this compliance policy, or if our products become subject to increased regulatory compliance burdens imposed by the FDA and other regulatory or legislative bodies.
Since their introduction, there has been significant uncertainty regarding whether, how and when tobacco regulations would apply to NewGen products, such as electronic cigarettes or other vaporizer products. Based on a decision in December 2010 by the U.S. Court of Appeals for the D.C. Circuit (the “Sottera decision”), the FDA is permitted to regulate electronic cigarettes containing tobacco-derived nicotine as “tobacco products” under the Tobacco Control Act.
Effective August 8, 2016, FDA’s regulatory authority under the Tobacco Control Act was extended to all remaining tobacco products, including: (i) certain NewGen products (such as electronic cigarettes, vaporizers and e-liquids) and their components or parts (such as tanks, coils and batteries); (ii) cigars and their components or parts (such as cigar tobacco); (iii) pipe tobacco; (iv) hookah products; or (v) any other tobacco product “newly deemed” by FDA. These deeming regulations apply to all products made or derived from tobacco intended for human consumption, but excluding accessories of tobacco products (such as lighters).
The deeming regulations require us to (i) register with the FDA and report product and ingredient listings; (ii) market newly deemed products only after FDA review and approval; (iii) only make direct and implied claims of reduced risk if the FDA approves after finding that scientific evidence supports the claim and that marketing the product will benefit public health as a whole; (iv) refrain from distributing free samples; (v) implement minimum age and identification restrictions to prevent sales to individuals under age 18; (vi) develop an approved warning plan and include prescribed health warnings on packaging and advertisements; and (vii) refrain from selling the products in vending machines, unless the machine is located in a facility that never admits youth. Newly deemed tobacco products are also subject to the other requirements of the Tobacco Control Act, such as that they not be adulterated or misbranded. The FDA could in the future promulgate good manufacturing practice regulations for these and our other products, which could have a material adverse impact on our ability and the cost to manufacture our products.
Marketing authorizations will be necessary in order for us to continue our distribution of NewGen and cigar products. The FDA has announced various compliance policies whereby it does not intend to prioritize enforcement for lack of premarket authorization against newly-deemed products, provided that such tobacco products were marketed as of August 8, 2016; are not marketed in certain manners likely to be attractive to youth; and for which premarket applications were timely submitted. As a result of recent litigation and subsequent FDA Guidance, marketing applications for newly-deemed products were required to have been submitted no later than September 9, 2020, with the exception of our “grandfathered” products (products in commerce as of February 15, 2007) which are already authorized. Under the FDA’s compliance policy, such products could remain on the market until September 9, 2021, unless the FDA makes an adverse determination prior to that date. Subsequent to September 9, 2021, FDA indicated its enforcement priority is those applicants who have received negative action on their application, such as a Marketing Denial Order or Refuse to File notification and who continue to illegally sell those unauthorized products, as well as products for which manufacturers failed to submit a marketing application.
In September 2020, we submitted applications on a timely basis for the appropriate authorizations for our products that are deemed products not otherwise grandfathered. We believe that these products satisfy the criteria for current marketing pursuant to the FDA’s compliance policy. However, there can be no guarantee that the FDA will agree, and the FDA may bring an enforcement action against our products for lack of premarket authorization and/or deny our premarket applications. We have no assurances that the outcome of such application review processes will result in our products receiving marketing authorizations from the FDA. For instance, on September 14, 2021, the FDA issued an MDO for certain of the Company’s proprietary e-liquid products subject of these PMTAs. The Company filed a Petition for Review in the Sixth Circuit Court of Appeals on September 23, 2021, followed by an Emergency Motion for a Stay Pending Review on September 30, 2021. On October 7, 2021, we were informed that the FDA had rescinded its September 14 MDO. We therefore withdrew both the Petition and Emergency Stay on October 8, 2021. The Rescission Letter indicated that FDA had found additional relevant information that was not adequately assessed. If the FDA were to issue additional MDOs that remained effective it could have an adverse effect on our business.
We also have certain previously regulated tobacco products which FDA removed from review but remain subject to “provisional” substantial equivalence submissions made on March 22, 2011; however, FDA has the discretion to reinitiate review of these products. If the FDA establishes regulatory processes that we are unable or unwilling to comply with, our business, results of operations, financial condition and prospects could be adversely affected.
The anticipated costs of complying with future FDA regulations will be dependent on the rules issued by the FDA, the timing and clarity of any new rules or guidance documents accompanying these rules, the reliability and simplicity (or complexity) of the electronic systems utilized by FDA for information and reports to be submitted, and the details required by FDA for such information and reports with respect to each regulated product. Failure to comply with existing or new FDA regulatory requirements could result in significant financial penalties and could have a material adverse effect on our business, results of operations, financial condition and ability to market and sell our products. Compliance and related costs could be substantial and could significantly increase the costs of operating in our NewGen and cigar product markets.
In addition, failure to comply with the Tobacco Control Act and with FDA regulatory requirements could result in litigation, criminal convictions or significant financial penalties and could impair our ability to market and sell certain of our NewGen and cigar products. At present, we are not able to predict whether the Tobacco Control Act will impact our products to a greater degree than competitors in the industry, thus affecting our competitive position.
Furthermore, in addition to the FDA, there are restrictions being proposed or in effect at the federal, state, and local level related to these products. For example, the PACT Act has now been amended to apply to certain NewGen products, which has impacts at the federal and state levels. These requirements are in addition to any increased regulation of internet sales that may be in effect or passed legislatively at the federal, state, or local levels, or promulgated via rulemaking by a government agency. Additionally, state attorneys general have monitored, and in some cases, have issued investigative requests to companies that sell these products related to online sales, marketing practices, and other aspects of the NewGen business. Increased regulation of additives in tobacco products through federal, state, or local governments may also adversely affect NewGen and cigar products. The application of these types of restrictions, and of any new laws or regulations which may be adopted in the future, to these products could result in additional expenses and require us to change our advertising and labeling, and methods of marketing and distribution of our products, any of which could have a material adverse effect on our business, results of operations and financial condition.
Some of our products are subject to developing and unpredictable regulation.
Some of our NewGen products marketed through our Nu-X subsidiary and similar third-party products sold through our NewGen distribution vehicles may be subject to uncertain and evolving federal, state and local regulations concerning hemp, CBD and other non-tobacco consumable products. Enforcement initiatives by those authorities are therefore unpredictable and impossible to anticipate. We anticipate that all levels of government, which have not already done so, are likely to seek in some way to regulate these products, but the type, timing, and impact of such regulations remains uncertain. These regulations include or could include restrictions including prohibitions on certain form factors, such as smokable hemp products, or age restrictions. Accordingly, we cannot give any assurance that such actions would not have a material adverse effect on this emerging business.
For instance, on October 21, 2021, the USPS published a Final Rule entitled “Treatment of E-Cigarettes in the Mail,” which followed its earlier publication of the Proposed Rule on February 19, 2021. This Final Rule was required as a result of the inclusion of POSECA in the Further Consolidated Appropriations Act, 2021. POSECA, among other things, expanded the definition of “cigarettes” in the Jenkins Act and PACT Act to expressly capture ENDS. Consistent with the Proposed Rule, the Final Rule extends the existing prohibition on and exceptions to the mailing of “cigarettes” via USPS to include ENDS products, other than the Consumer Testing and Public Health exceptions. POSECA’s definition of ENDS also captures non-tobacco products, such as e-liquids that do not contain tobacco-derived nicotine.
The COVID-19 Pandemic and related economic repercussions may affect our business.
The COVID-19 pandemic and related economic repercussions have created significant volatility, uncertainty, and turmoil in businesses globally. While these events have not yet had a material adverse effect on our business and B2C platforms like ours have seen elevated sales levels from consumer shifts to online purchasing, we can offer no assurance that the COVID-19 pandemic will not have an adverse effect in the future, particularly if the pandemic worsens or endures for an extended period of time.
At the onset of the pandemic we implemented several changes to enhance safety and mitigate health risk in our work environment. For our warehouse and manufacturing operations, these included split shifts, temperature scans, additional contactless hand sanitizing stations, protective equipment, social distancing guidelines, and increased cleaning and sanitization. These changes resulted in higher operational costs, and as a result, we instituted cost savings programs to offset these increased costs. We also put a hold on new spending commitments as we cautiously manage through this environment.
The COVID-19 pandemic may adversely impact our results. Our third-party cigar wrap manufacturer in the Dominican Republic was initially temporarily shut down, but after the initial temporary shutdown, has been operating without interruption related to COVID-19. Our supply chain has remained operational otherwise, but we can offer no assurance that it will not be adversely affected in the future, particularly as the COVID-19 pandemic continues to worsen. Similarly, because we have more than 100 employees, we are subject to proposed federal testing requirements, which could affect our workforce and ultimately our results of operations if we have a significant number of employees unwilling to comply with such mandates.
If the impact of the COVID-19 pandemic continues for an extended period of time or worsens, it could have a material adverse effect on our supply chain or workforce, either of which could have a material adverse effect on our business, financial condition and liquidity. In addition, if the impact of the COVID-19 pandemic continues it may heighten the other risks that could affect our business.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On February 25, 2020, the Company’s Board of Directors approved a $50.0 million share repurchase program, which is intended for opportunistic execution based upon a variety of factors including market dynamics. This share repurchase program has no expiration date and is subject to the ongoing discretion of the Board. All repurchases to date under our stock repurchase programs have been made through open market transactions, but in the future, we may also purchase shares through privately negotiated transactions or 10b5-1 repurchase plans. On October 25, 2021, the Board increased the approved share repurchase program by $30.7 million.
The following table includes information regarding purchases of our common stock made by us during the quarter ended September 30, 2021 in connection with the repurchase program described above:
Period | | Total Number of Shares Purchased | | | Average Price Paid per Share | | | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | | | Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs | |
July 1 to July 31 | | | - | | | $ | - | | | | - | | | $ | 25,723,385 | |
August 1 to August 31 | | | 125,000 | | | $ | 51.16 | | | | 125,000 | | | $ | 19,328,385 | |
September 1 to September 30 | | | - | | | $ | - | | | | - | | | $ | 19,328,385 | |
Total | | | 125,000 | | | | | | | | 125,000 | | | | | |
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None
Exhibit No. | Description |
| |
| Preferability letter from RSM US, LLP regarding a change in accounting method. (incorporated by reference to Exhibit 18.1 to the Registrant’s Quarterly Report on Form 10-Q filed on May 5, 2021) |
| |
| Rule 13a-14(a)/15d-14(a) Certification of Lawrence S. Wexler.* |
| |
| Rule 13a-14(a)/15d-14(a) Certification of Luis Reformina.* |
| |
| Rule 13a-14(a)/15d-14(a) Certification of Brian Wigginton.* |
| |
| Section 1350 Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* |
| |
101 | XBRL (eXtensible Business Reporting Language). The following materials from Turning Point Brands, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on October 26, 2021, formatted in Inline XBRL (iXBRL): (i) consolidated balance sheets, (ii) consolidated statements of income, (iii) consolidated statements of comprehensive income, (iv) consolidated statements of cash flows, and (v) the notes to consolidated financial statements.* |
| |
104 | Cover Page Interactive Data File (formatted in iXBRL and included in Exhibit 101).* |
* Filed or furnished herewith
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| TURNING POINT BRANDS, INC. | |
| | | | |
| | By: /s/ Lawrence S. Wexler | |
| | Name: Lawrence S. Wexler | |
| | | Title: President and Chief Executive Officer | |
| | | | |
| | By: /s/ Luis Reformina | |
| | Name: Luis Reformina | |
| | | Title: Chief Financial Officer | |
| | | | |
| | By: /s/ Brian Wigginton | |
| | Name: Brian Wigginton | |
| | | Title: Chief Accounting Officer | |
Date: October 26, 2021